Key facts
- ImmunoScape’s last known valuation is $80.8M (Jun 2025).
- It has raised $60.4M; the latest was Angel (individual) ($33.3M) in Mar 2026.
- Notable investors include EDBI, Johnson & Johnson Innovation - JLABS, The University of Tokyo Edge Capital, Leonardo DiCaprio, Accelerate Technologies — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for ImmunoScape
- ·The full record, as it builds
Funding rounds
No funding rounds for ImmunoScape are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImmunoScape
Developer of an immune profiling system and analytical tools designed to support immunotherapy clinical development. The company's tools offer immune cell profiling technologies, antigen-specific T-cell identification, and an online analytical pipeline, enabling companies to gain valuable information on the efficacy and safety of immunotherapies across the research, development, and clinical phases.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2016
- Employees
- 23
- Website
- immunoscape.com/
- Ownership
- Privately Held (backing)
ImmunoScape doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmunoScape shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmunoScape in its N-PORT filings yet. We sweep new filings monthly.